Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

Dr David Johnson selects his 10 highest-impact publications from 2025, which define new management standards across a broad spectrum of diseases.

The main market opportunities lie in developing comprehensive training and support services for implementing and integrating clinical quality management systems (CQMS) that align with evolving ...

The market opportunity lies in providing training and tools for EU RMP compliance, focusing on creating and updating RMPs per regulatory standards. Key services include offering practical guidance on ...

Introduction Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20–25% of affected individuals ...

Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses ...

Bioassay variability can pose significant challenges due to laboratory conditions, instrumentation, analytical software, cell ...

Press Release Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026All clinical trial and ...

The closing ceremony was hosted in the evening by India at the temporary pavilion, Plenary Hall, at the fort complex, as ...

At CDMI Europe 2025, experts agreed that AI is the key technology to improve efficiencies in clinical trial data management.